8-K: Altimmune Completes Enrollment in Key MASH Trial, Advances Obesity Program

Altimmune announced the completion of enrollment in its Phase 2b MASH trial and provided updates on its obesity program, including a successful meeting with the FDA.

Summary

• Altimmune has completed enrollment in the Phase 2b IMPACT trial for pemvidutide in MASH, with top-line efficacy data expected in Q2 2025.
• The company successfully completed an End-of-Phase 2 meeting with the FDA for its pemvidutide obesity program, agreeing on the design for four pivotal Phase 3 trials.
• These Phase 3 trials will focus on weight loss and the impact of pemvidutide on obesity-related comorbidities.
• Altimmune plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications, starting in Q4 2024.
• The company reported cash, cash equivalents, and short-term investments of $139.4 million as of September 30, 2024.
• Research and development expenses were $19.8 million for the quarter ended September 30, 2024, compared to $18.4 million in the same period in 2023.
• The net loss for the quarter was $22.8 million, or $0.32 per share, compared to a net loss of $20.7 million, or $0.39 per share, in the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and a solid cash position. However, the increased net loss and R&D expenses temper the overall sentiment slightly.

Positives

• The completion of enrollment in the Phase 2b IMPACT trial is a significant milestone for the MASH program.
• Successful agreement with the FDA on the Phase 3 obesity program design de-risks the path to potential approval.
• Pemvidutide has demonstrated strong lean mass preservation and visceral fat reduction, which are key differentiators.
• The company has a solid cash position of $139.4 million.
• The planned expansion of pemvidutide into additional indications broadens its potential market.

Negatives

• The company reported a net loss of $22.8 million for the quarter ended September 30, 2024, which is an increase from the $20.7 million loss in the same period in 2023.
• Research and development expenses increased to $19.8 million for the quarter, compared to $18.4 million in the same period in 2023.
• General and administrative expenses also increased to $5.0 million for the quarter, compared to $4.5 million in the same period in 2023.

Risks

• The company faces risks related to delays in regulatory review and potential manufacturing and supply chain interruptions.
• There are risks associated with clinical trial enrollment and potential adverse effects from the administration of the company's product candidates.
• The success of future product advancements, including clinical trials, is not guaranteed.
• The company's ability to manufacture clinical trial materials on the anticipated timelines is a risk.

Future Outlook

Altimmune anticipates 2025 to be a transformational year for pemvidutide, with multiple key inflection points on the horizon, including the release of top-line data from the Phase 2b IMPACT trial and the initiation of Phase 3 trials for obesity.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer, stated that the completion of enrollment in the Phase 2b IMPACT trial positions the company to report top-line efficacy data in Q2 2025.
• Dr. Garg also noted the successful completion of the End-of-Phase 2 meeting with the FDA for the pemvidutide Phase 3 obesity program.
• Scott Harris, M.D., Chief Medical Officer, highlighted the compelling data from the Phase 2 MOMENTUM trial, showing class-leading lean mass preservation and preferential reduction in visceral adipose tissue.

Industry Context

This announcement is significant in the context of the growing market for MASH and obesity treatments. The successful completion of enrollment in the MASH trial and the agreement with the FDA for the obesity program position Altimmune as a potential key player in these therapeutic areas. The focus on lean mass preservation is a differentiator in the competitive obesity market.

Comparison to Industry Standards

• The reported lean loss ratio of 21.9% in the MOMENTUM trial is competitive with other GLP-1 based therapies, with the 19.9% in older patients being particularly notable.
• The 28.3% reduction in visceral adipose tissue is a strong result compared to other obesity treatments, as VAT is a key indicator of cardiovascular risk.
• The company's approach of targeting both GLP-1 and glucagon receptors is a differentiating factor compared to single-agonist therapies.
• Other companies such as Viking Therapeutics and Madrigal Pharmaceuticals are also developing MASH treatments, making the competitive landscape intense.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the progress of the clinical trials and the potential for future revenue.
• Employees will be impacted by the company's growth and the potential for new opportunities.
• Patients will benefit from the development of new treatments for MASH and obesity.
• The company's suppliers and partners will be impacted by the increased activity in clinical trials and product development.

Next Steps

• The company plans to submit IND applications for pemvidutide in up to three additional indications.
• The first of these IND applications will be submitted in Q4 2024.
• The company will initiate the first trial for an additional indication in H1 2025.
• Top-line efficacy data from the Phase 2b IMPACT trial is expected in Q2 2025.
• The company will proceed with four Phase 3 clinical trials for pemvidutide in obesity.

Key Dates

Keywords

pemvidutide, MASH, obesity, clinical trials, FDA, GLP-1, glucagon, weight loss, lean mass, biopharmaceutical